MBX Biosciences (MBX) Depreciation & Amortization (CF) (2023 - 2026)

MBX Biosciences has disclosed Depreciation & Amortization (CF) across 4 years of filings, most recently posting $64000.0 for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $64000.0, down 16.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $312000.0 (down 2.8% YoY), and the FY2025 annual result was $248000.0, up 1.64% from the prior year.
• Depreciation & Amortization (CF) came in at $64000.0 for Q1 2026 at MBX Biosciences, up from $48000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $100000.0 in Q3 2023 to a low of $41000.0 in Q4 2023.
• The 4-year median for Depreciation & Amortization (CF) is $77000.0 (2025), against an average of $74727.3.
• Across the five-year window, Depreciation & Amortization (CF) surged 60.42% in 2025 and fell 16.88% in 2026, its largest moves.
• MBX Biosciences' Depreciation & Amortization (CF) stood at $41000.0 in 2023, then rose by 7.32% to $44000.0 in 2024, then climbed by 9.09% to $48000.0 in 2025, then surged by 33.33% to $64000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $64000.0 (Q1 2026), $48000.0 (Q4 2025), and $100000.0 (Q3 2025), per Business Quant data.